Biosimilar Drug Approval
Aurobindo Pharma Subsidiary CuraTeQ Receives Health Canada NOC for Bevacizumab Biosimilar Bevqolva
NSE
auropharma
BSE
524804
Aurobindo Pharma’s wholly owned subsidiary CuraTeQ Biologics has received regulatory approval (NOC) from Health Canada for its bevacizumab biosimilar Bevqolva, enabling commercialization in the Canadian oncology market
PRICE-SENSITIVE TRIGGER
Event: Regulatory Approval (Health Canada NOC)
Type: Biosimilar Drug Approval
Impact: Positive
Immediate Effect: StrOpens access to the Canadian biologics market, strengthening Aurobindo’s biosimilar portfolio and global presence
What Happened ?
CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has received a Notice of Compliance (NOC) from Health Canada for its biosimilar Bevqolva™ (bevacizumab).
This approval confirms that the product meets regulatory standards for safety, efficacy, and quality, enabling its commercialization in Canada.
key highlights
Product Overview:
- Product: Bevqolva™ (Bevacizumab Biosimilar)
- Therapeutic area: Oncology
- Mechanism:
- Inhibits VEGF-A
- Prevents tumor blood vessel formation (anti-angiogenesis)
- Indications:
- Colorectal cancer
- Lung cancer
Regulatory & Market Expansion:
- Approved by Health Canada (BRDD division)
- Follows earlier:
- UK approval (MHRA)
- Commercial launch in UK (2025)
- Under review:
- European Medicines Agency (CHMP)
- Additional biosimilars under review in Canada
Competitive Landscape:
- Reference drug: Avastin (Roche/Genentech)
- Biosimilar provides:
- Cost-effective alternative
- Improved accessibility in oncology treatment
Product Specifications:
- Available in:
- 100 mg
- 400 mg formulations
- Comparable to originator biologic
Strategic Importance:
- Strengthens Aurobindo’s biosimilar pipeline
- Expands presence in regulated markets
- Moves up value chain from generics to biologics
- Enhances long-term growth visibility
Note:
Revenue contribution will depend on commercialization timeline and market penetration in Canada
Risk Analysis
Key Risks
- Intense competition in biosimilars market
- Pricing pressure vs originator and other biosimilars
- Regulatory delays in other regions
- Execution risk in scaling biologics business
Worst Case Scenario
- Slow market uptake or pricing pressure could limit revenue impact despite approval
Risk Level: Medium
Company Commentary
- Approval confirms compliance with global regulatory standards
- Product demonstrates comparable safety, efficacy, and quality
- Builds on prior approvals in UK and ongoing EU review
- Reinforces commitment to biosimilar expansion
Official Exchange Filing: Aurobindo Pharma Limited